NR4A1 and breast cancer: Four articles (50%) enrolled patients with all molecular subtypes [54,56,57,58], two focused on patients with HER2-positive BC [55,61], one on patients with TNBC [60] and one on patients with hormone receptor-positive BC receiving hormone therapy as initial treatment [59](Table 5).